A nanomedicine approach for the treatment of long-lasting pain

Hazam, Hadjer; Prades, Lucas; Cailleau, Catherine; Mougin, Julie; Feng, Jiao; Benhamou, Dan; Gobeaux, Frédéric; Hamdi, Leïla; Couvreur, Patrick; Sitbon, Philippe; Lepetre-Mouelhi, Sinda

doi:10.1016/j.jconrel.2024.07.033

Journal of Controlled Release

2024

DOI: 10.1016/j.jconrel.2024.07.033

|View full text |Cite

A nanomedicine approach for the treatment of long-lasting pain

Hadjer Hazam,

Lucas Prades,

Catherine Cailleau

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Intrinsic anti-inflammatory nanomedicines for enhanced pain management

Qiao,

Yao,

Fan

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

IntroductionEffective postoperative pain management remains a significant challenge due to the severe side effects of opioids and the limitations of existing analgesic delivery systems. Inflammation plays a critical role in pain exacerbation, highlighting the need for therapies that combine analgesic effects with intrinsic anti-inflammatory properties.MethodsHerein, we develop an intrinsic anti-inflammatory nanomedicine designed to enhance pain management by integrating controlled anesthetic release with inherent anti-inflammatory activity. Our nanoplatform utilizes dendritic mesoporous silica nanoparticles (MSNs) loaded with levobupivacaine and coated with Rg3-based liposomes derived from ginsenoside Rg3, termed LMSN-bupi.ResultsThe MSNs enable sustained and controlled release of the local anesthetic, while the Rg3-liposome coating provides intrinsic anti-inflammatory effects by inhibiting macrophage activation. In animal models, LMSN-bupi demonstrates significantly prolonged analgesic effects and attenuated inflammatory responses compared to traditional liposome-decorated nanoparticles (TMSN-bupi) (n = 5).DiscussionThese findings underscore the potential of intrinsic anti-inflammatory nanomedicines in enhancing pain management, offering a promising strategy to overcome the limitations of current therapies and improve patient outcomes in postoperative care.

show abstract

Intrinsic anti-inflammatory nanomedicines for enhanced pain management

Qiao,

Yao,

Fan

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A nanomedicine approach for the treatment of long-lasting pain

Cited by 1 publication

References 35 publications

Intrinsic anti-inflammatory nanomedicines for enhanced pain management

Intrinsic anti-inflammatory nanomedicines for enhanced pain management

Contact Info

Product

Resources

About